The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nedogoda S.V.

Volgograd State Medical University

Chumachek E.V.

Volgograd State Medical University

Ledyaeva A.A.

Volgograd State Medical University

Tsoma V.V.

Volgograd State Medical University

Vlasov D.S.

Volgograd State Medical University

Bychkova O.I.

Medical Department of the Federal Security Service of Russia in the Volgograd Region

Non-fixed combination perindopril+moxonidine for blood pressure control in hypertensive patients with metabolic syndrome

Authors:

Nedogoda S.V., Chumachek E.V., Ledyaeva A.A., Tsoma V.V., Vlasov D.S., Bychkova O.I.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(2): 208‑214

DOI: 10.17116/kardio202114021208

Views: 8440

Downloaded: 136

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma VV, Vlasov DS, Bychkova OI. Non-fixed combination perindopril+moxonidine for blood pressure control in hypertensive patients with metabolic syndrome. Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(2):208‑214. (In Russ.)
https://doi.org/10.17116/kardio202114021208

 
МСФ на ЯМ
Close metadata

OBJECTIVE

To evaluate the non-fixed combination perindopril + moxonidine in blood pressure (BP) control (<130/80 mm Hg) in patients with hypertension, metabolic syndrome and previous combined antihypertensive therapy.

MATERIAL AND METHODS

The open observational 24-week study included 72 patients. All patients underwent ambulatory BP monitoring and laboratory tests (lipid profile, uric acid, HOMA index, leptin, serum catecholamines).

RESULTS

Non-fixed combination perindopril + moxonidine 0.4 or 0.6 mg ensured systolic BP reduction by 24.8% and 20.9%, diastolic BP decrease by 19.4% and 17.4%, respectively (p<0.05). The target BP (<130 mm Hg) was achieved in 64.6% and 63.6% of patients, respectively. We found leptin level reduction by 18.0% and 6.7%, uric acid by 15.2% and 14.9%, HOMA index by 7.7% and 4.8% (p<0.05), norepinephrine by 10.8% and 17.6% (p<0.05), dopamine by 14.6% and 14.0%, respectively (p<0.05).

CONCLUSION

Non-fixed combination perindopril + moxonidine has advantages in BP control, suppression of insulin resistance and sympathetic hyperactivity.

Keywords:

arterial hypertension
insulin resistance
catecholamines
sympathetic hyperactivity
perindopril
moxonidine

Authors:

Nedogoda S.V.

Volgograd State Medical University

Chumachek E.V.

Volgograd State Medical University

Ledyaeva A.A.

Volgograd State Medical University

Tsoma V.V.

Volgograd State Medical University

Vlasov D.S.

Volgograd State Medical University

Bychkova O.I.

Medical Department of the Federal Security Service of Russia in the Volgograd Region

Received:

20.02.2020

Accepted:

10.03.2020

List of references:

  1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;10:1-98.  https://doi.org/10.1093/eurheartj/ehy339
  2. Shlyahto EV, Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Guidelines for the management of arterial hypertension. 2020. (In Russ.). https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf
  3. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012—2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.). https://doi.org/10.15829/1728-8800-2014-6-4-11
  4. Oshchepkova EV, Lazareva NV, Chazova IE. Features of the clinics and treatment of patients with obesity and hypertension (according to the National register of arterial hypertension). Terapevticheskiy arkhiv. 2018;9:8-14. (In Russ.). https://doi.org/10.26442/terarkh20189098-14
  5. Chazova IE, Mychka VB. Novye vozmozhnosti v lechenii bol’nykh s metabolicheskim sindromom (rezul’taty issledovaniya ALMAZ). Sistemnye gipertenzii. 2006;2:14-17. (In Russ.).
  6. Chazova IE, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens. 2013;541689. https://doi.org/10.1155/2013/541689
  7. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin. 2004;20(3):359-367.  https://doi.org/10.1185/030079904125002991
  8. Carnagarin R, Gregory C, Azzam O. The Role of Sympatho-inhibition in combination treatment of obesity-related hypertension. Curr Hypertens Rep. 2017;19:99.  https://doi.org/10.1007/s11906-017-0795-1
  9. Dampney R. Arcuate nucleus — a gateway for insulin’s action on sympathetic activity. J Physiol. 2011;589(9):2109-2110. https://doi.org/10.1113/jphysiol.2011.208579
  10. Ionescu DD. PREFER Investigators. Antihypertensive efficacy of perindopril 5—10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig. 2009;29(12):767-776.  https://doi.org/10.2165/11319700-000000000-00000
  11. Koz C, Baysan O, Yokusoglu M, et al. The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Med Sci Monit. 2009;15(7):PI41-45. 
  12. Prichard BN, Jäger BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press. 2002;11(3):166-172.  https://doi.org/10.1080/080370502760050403
  13. Frei M, Küster L, Gardosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol. 1994;24(suppl 1):25-28.  https://doi.org/10.1097/00005344-199424001-00005
  14. Waters J, Ashford J, Jager BA, et al. Use of moxonidine as unitial therapy and in combination in the treatment of essential hypertension: results of the TOPIC study. J Clin Basic Cardiol. 1999;2:219-224. 
  15. White WB. Ambulatory blood pressure monitoring: dippers compared with non-dippers. Blood Press Monit. 2000;5(suppl 1):17-23. 
  16. Wyss JM, Carlson SH. The Role of the Nervous System in Hypertension Current Hypertension Reports. 2001;3:255-262.  https://doi.org/10.1007/s11906-001-0048-0
  17. Gaponova NI, Abdrakhmanov VR, Tereshchenko SN. Vozmozhnosti moksonidina v lechenii arterial’noy gipertonii i oslozhneniy. Effektivnaya farmakoterapiya. 2013;11(1):12-18. (In Russ).
  18. Sanjuliani AF, Francischetti EA, Genelhu de Abreu V. et al. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J Clin Basic Cardiol. 2004;7:19.  https://doi.org/10.4103/0975-7406.120067
  19. Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2004;112:315-322.  https://doi.org/10.1055/s-2004-820915
  20. Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract. 2004;58:465-468.  https://doi.org/10.1111/j.1368-5031.2004.00158.x
  21. Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:300-312.  https://doi.org/10.1007/s00210-005-0024-3
  22. Edwards LP, Brown-Bryan TA, McLean L. Pharmacological properties of the central antihypertensive agent moxonidine. Cardiovascular Therapeutics. 2011;10:1-10.  https://doi.org/10.1111/j.1755-5922.2011.00268.x
  23. Zhernakova JuV, Chazova IE. The ability of imidazoline receptors agonist moxonidine in the treatment of patients with arterial hypertension and metabolic disorders: final results of the MERSY study. Systemic hypertension. 2013;2:34-40. (In Russ.). https://doi.org/10.1155/2013/541689
  24. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928-933.  https://doi.org/10.1253/circj.69.928
  25. Goya W, Shaper G, Whincup P. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78:147-153.  https://doi.org/10.1136/hrt.78.2.147

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.